Literature DB >> 32759358

Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.

Francesco Maura1, Ola Landgren1, Gareth J Morgan2.   

Abstract

The development of next-generation sequencing technology has dramatically improved our understanding of the genetic landscape of multiple myeloma. Several new drivers and recurrent events have been reported and linked to a potential driver role. This complex landscape is enhanced by intraclonal mutational heterogeneity and variability introduced through the dimensions of time and space. The evolutionary history of multiple myeloma is driven by both the accumulation of different genomic drivers and by the activity of different mutational processes active overtime. In this review, we describe how these new findings and sequencing technologies have been progressively allowed to understand and reshape our knowledge of the complexity of multiple myeloma at each of its developmental stages: premalignant, at diagnosis, and in relapsed/refractory states. We discuss how these evolutionary concepts can be utilized in the clinic to alter evolutionary trajectories providing a framework for therapeutic intervention at early-disease stages. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32759358      PMCID: PMC7785564          DOI: 10.1158/1078-0432.CCR-20-1395

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  68 in total

Review 1.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors:  Helen Davies; Dominik Glodzik; Sandro Morganella; Lucy R Yates; Johan Staaf; Xueqing Zou; Manasa Ramakrishna; Sancha Martin; Sandrine Boyault; Anieta M Sieuwerts; Peter T Simpson; Tari A King; Keiran Raine; Jorunn E Eyfjord; Gu Kong; Åke Borg; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; Anne-Lise Børresen-Dale; John W M Martens; Paul N Span; Sunil R Lakhani; Anne Vincent-Salomon; Christos Sotiriou; Andrew Tutt; Alastair M Thompson; Steven Van Laere; Andrea L Richardson; Alain Viari; Peter J Campbell; Michael R Stratton; Serena Nik-Zainal
Journal:  Nat Med       Date:  2017-03-13       Impact factor: 53.440

3.  Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.

Authors:  Aneta Mikulasova; Jan Smetana; Marketa Wayhelova; Helena Janyskova; Viera Sandecka; Zuzana Kufova; Martina Almasi; Jiri Jarkovsky; Evzen Gregora; Petr Kessler; Marek Wrobel; Brian A Walker; Christopher P Wardell; Gareth J Morgan; Roman Hajek; Petr Kuglik
Journal:  Eur J Haematol       Date:  2016-06-09       Impact factor: 2.997

4.  Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Jihye Park; Robert Redd; Benny Zhitomirsky; Andrew J Dunford; Karma Salem; Yu-Tzu Tai; Shankara Anand; Tarek H Mouhieddine; Selina J Chavda; Cody Boehner; Liudmila Elagina; Carl Jannes Neuse; Justin Cha; Mahshid Rahmat; Amaro Taylor-Weiner; Eliezer Van Allen; Shaji Kumar; Efstathis Kastritis; Ignaty Leshchiner; Elizabeth A Morgan; Jacob Laubach; Tineke Casneuf; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson; Lorenzo Trippa; François Aguet; Chip Stewart; Meletios-Athanasios Dimopoulos; Kwee Yong; P Leif Bergsagel; Salomon Manier; Gad Getz; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 50.717

5.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

6.  Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.

Authors:  Rituparna Das; Till Strowig; Rakesh Verma; Srinivas Koduru; Anja Hafemann; Stephanie Hopf; Mehmet H Kocoglu; Chiara Borsotti; Lin Zhang; Andrew Branagan; Elizabeth Eynon; Markus G Manz; Richard A Flavell; Madhav V Dhodapkar
Journal:  Nat Med       Date:  2016-10-10       Impact factor: 53.440

7.  Deciphering the chronology of copy number alterations in Multiple Myeloma.

Authors:  Anil Aktas Samur; Stephane Minvielle; Masood Shammas; Mariateresa Fulciniti; Florence Magrangeas; Paul G Richardson; Philippe Moreau; Michel Attal; Kenneth C Anderson; Giovanni Parmigiani; Hervé Avet-Loiseau; Nikhil C Munshi; Mehmet Kemal Samur
Journal:  Blood Cancer J       Date:  2019-03-26       Impact factor: 11.037

8.  The repertoire of mutational signatures in human cancer.

Authors:  Ludmil B Alexandrov; Jaegil Kim; Gad Getz; Steven G Rozen; Michael R Stratton; Nicholas J Haradhvala; Mi Ni Huang; Alvin Wei Tian Ng; Yang Wu; Arnoud Boot; Kyle R Covington; Dmitry A Gordenin; Erik N Bergstrom; S M Ashiqul Islam; Nuria Lopez-Bigas; Leszek J Klimczak; John R McPherson; Sandro Morganella; Radhakrishnan Sabarinathan; David A Wheeler; Ville Mustonen
Journal:  Nature       Date:  2020-02-05       Impact factor: 49.962

9.  Clock-like mutational processes in human somatic cells.

Authors:  Ludmil B Alexandrov; Philip H Jones; David C Wedge; Julian E Sale; Peter J Campbell; Serena Nik-Zainal; Michael R Stratton
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

10.  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Authors:  Brian A Walker; Konstantinos Mavrommatis; Christopher P Wardell; T Cody Ashby; Michael Bauer; Faith Davies; Adam Rosenthal; Hongwei Wang; Pingping Qu; Antje Hoering; Mehmet Samur; Fadi Towfic; Maria Ortiz; Erin Flynt; Zhinuan Yu; Zhihong Yang; Dan Rozelle; John Obenauer; Matthew Trotter; Daniel Auclair; Jonathan Keats; Niccolo Bolli; Mariateresa Fulciniti; Raphael Szalat; Phillipe Moreau; Brian Durie; A Keith Stewart; Hartmut Goldschmidt; Marc S Raab; Hermann Einsele; Pieter Sonneveld; Jesus San Miguel; Sagar Lonial; Graham H Jackson; Kenneth C Anderson; Herve Avet-Loiseau; Nikhil Munshi; Anjan Thakurta; Gareth Morgan
Journal:  Leukemia       Date:  2018-07-02       Impact factor: 11.528

View more
  8 in total

Review 1.  Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.

Authors:  Monika Chojnacka; Benjamin Diamond; Ola Landgren; Francesco Maura
Journal:  Semin Oncol       Date:  2022-01-31       Impact factor: 5.385

3.  The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.

Authors:  Bénedith Oben; Charlotte Cosemans; Ellen Geerdens; Loes Linsen; Kimberly Vanhees; Brigitte Maes; Koen Theunissen; Bert Cruys; Marta Lionetti; Ingrid Arijs; Niccolò Bolli; Guy Froyen; Jean-Luc Rummens
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

4.  Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.

Authors:  Bénedith Oben; Guy Froyen; Kylee H Maclachlan; Daniel Leongamornlert; Federico Abascal; Binbin Zheng-Lin; Venkata Yellapantula; Andriy Derkach; Ellen Geerdens; Benjamin T Diamond; Ingrid Arijs; Brigitte Maes; Kimberly Vanhees; Malin Hultcrantz; Elisabet E Manasanch; Dickran Kazandjian; Alexander Lesokhin; Ahmet Dogan; Yanming Zhang; Aneta Mikulasova; Brian Walker; Gareth Morgan; Peter J Campbell; Ola Landgren; Jean-Luc Rummens; Niccolò Bolli; Francesco Maura
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

Review 5.  Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.

Authors:  Samuel S McCachren; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 6.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

7.  Intratumor Epigenetic Heterogeneity-A Panel Gene Methylation Study in Thyroid Cancer.

Authors:  Chaofan Zhu; Meiying Zhang; Qian Wang; Jin Jen; Baoguo Liu; Mingzhou Guo
Journal:  Front Genet       Date:  2021-09-03       Impact factor: 4.599

8.  Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients.

Authors:  Widad Tahiru; Antonio Izarra Santamaria; Johan Hultdin; Wendy Yi-Ying Wu; Florentin Späth
Journal:  Exp Hematol Oncol       Date:  2022-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.